Efficacy and safety of SARS-CoV-2 neutralizing antibody, SCTA01, in high-risk outpatients diagnosed with COVID-19: A Phase II clinical trial by Jorge Diaz, Allex Fonseca, Lixin Yan, Dongfang Liu, Liangzhi Xie

Get full text

Fc-Modified Antibody in Hospitalized Severe COVID-19 Patients by Felipe Dal-Pizzol, Suzana Margareth Lobo, Christopher Lucasti, Adam Abdul Hakeem Baidoo, Huo Su, Zhanghua Lan, Liangzhi Xie

Get full text

Immunogenicity of monovalent and multivalent subunit vaccines against SARS-CoV-2 variants in mice with divergent vaccination history by Rui Wang, Yuan Lyu, Meng Chen, Lili Sun, Shaozheng Zhou, Yudi Cui, Juan Ma, Desheng Kong, Jianbo Lu, Xuefeng Li, Liangzhi Xie

Get full text

Preclinical Characterization of Efficacy and Pharmacodynamic Properties of Finotonlimab, a Humanized Anti-PD-1 Monoclonal Antibody by Yunqi Yao, Xiaoning Yang, Jing Li, Erhong Guo, Huiyu Wang, Chunyun Sun, Zhangyong Hong, Xiao Zhang, Jilei Jia, Rui Wang, Juan Ma, Yaqi Dai, Mingjing Deng, Chulin Yu, Lingling Sun, Liangzhi Xie

Get full text

Safety and Immunogenicity of the Tetravalent Recombinant COVID-19 Protein Vaccine SCTV01E in Children and Adolescents Aged 3 to 17 Years: A Randomized, Double-Blind, Placebo-Contro... by Fengcai Zhu, Ting Huang, Pengfei Jin, Linglin Zhang, Zhongqiang Jin, Wenli Zhang, Dongya Yuan, Zhong Wang, Yusong Deng, Jiaxin Li, Xiao Shen, Yongpan Fu, Jian Li, Xinjie Yang, Jing Li, Liangzhi Xie

Get full text

Intermediate-dose immune tolerance induction outperforms with faster success, less bleeding, and no added cost in comparison with low dose: a multicenter randomized clinical trial by Zhengping Li, Zekun Li, Xiaoling Cheng, Heng Zhang, Can Yang, Qian Xu, Zhenping Chen, Yingzi Zhen, Gang Li, Guoqing Liu, Wanru Yao, Min Zhou, Jiao Jin, Jie Huang, Yongjun Fang, Liangzhi Xie, Man-Chiu Poon, Runhui Wu

Get full text

Tip optofluidic immunoassay: Evaluating COVID-19 antibody protection with 1 μL fingertip blood by Xiaotian Tan, Yujuan Chai, Ruihan Li, Binmao Zhang, Hao Li, Jie Zhang, Tianen Zhu, Weishu Wu, Lixiang An, Shi Hu, Bin Yang, Li Wang, Zhenqiu Cao, Hongjiu Zhang, Peng Wang, Lingling Yu, Shan Yin, Xingyu Li, Fei Shao, Jianheng Huang, Jinze Li, Fan Yang, Chao Zhao, Jiajia Guo, Lin Zeng, Dong Liang, Zhengting Zou, Hairong Zheng, Xudong Fan, Liangzhi Xie, Yunlong Cao, Hui Yang

Get full text

Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial by Chuanhua Zhao, Yanqiao Zhang, Gang Wang, Jinfang Zheng, Weiqing Chen, Zheng Lu, Li Zhuang, Shanzhi Gu, Lei Han, Zhendong Zheng, Zujiang Yu, Yongsheng Yang, Hongmei Sun, Xiaoyong Wei, Ying Cheng, Hailan Lin, Bo Zhu, Guicheng Wu, Kaijian Lei, Wei Wang, Yuwen Wang, Kehe Chen, Ximing Xu, Cuiping Zheng, Yanzhi Bi, Sijuan Ding, Jingdong Zhang, Wei Li, Hailong Liu, Jun Wang, Xianling Liu, Yangfeng Du, Lianming Cai, Jingran Wang, Zhanxiong Luo, Baocai Xing, Jie Shen, Lin Yang, Jianbing Wu, Ou Jiang, Zhigang Peng, Xiuli Liu, Bangwei Cao, Liangfang Shen, Aibing Xu, Aimin Li, Shaojun Chen, Ting Fu, Jian Chen, Chuan Jin, Lei Zhang, Jun Lv, Chengwu Zhang, Xiaoman Zhang, Yu Wang, Huo Su, Qiang Zhou, Wenlin Gai, Liangzhi Xie, Jianming Xu

Get full text